As occurred in previous years, the HMR - Health Market Research, in partnership with CEFAR, has the pleasure to present you the new edition of the Study of Prescription, this year with the designation E-Prescription & Switch.
The great innovation incorporated in this study (2016) involves the collection and use of data from the Electronic Prescription.
The analyzes in question are supported in:
larger panel of participating pharmacies (450)
greater amount of evaluated prescriptions (> 5M),
more transactions obtained (> 10 million)
greater detail of information available in the study (includes prescription information beyond waived, allowing assess the effect of Switch and further detail by specialty).
The main objectives of the study undergo:
Quantify the proportion of drugs prescribed by Molecule (prescription made by CNPEM) or Molecule + brand (prescription made by CNP - Exceptions) when subject to replacement in GH.
In the case of exceptions, identify the differences between prescriptions and dispensation.
Characterization of prescribing and dispensing the identified Molecule.
Characterization, by medical specialty, prescription and exceptions.
Regional Characterization (5 areas Portugal Continental) with traveling.
Analysis Product / Molecule basket (originating from the prescription).
Client Market Analysis (junction PRD / Molecule).
Monthly Evolution (November 2015-May 2016).
If you want to know more about this study contact us.